Skip to content
Health — Health-and-wellness — Alzheimers-disease — Mental-health — Science — Medical-conditions — aging — Technology

FDA authorizes initial Alzheimer's diagnosis through blood test

Blood testing for early detection of Alzheimer's gets FDA approval, eliminating expensive and intrusive methods.

,   and  Administrator
3 min read
New Alzheimer's diagnostic tool, Lumipulse, approved by FDA, eliminates pricey and intrusive...
New Alzheimer's diagnostic tool, Lumipulse, approved by FDA, eliminates pricey and intrusive examination methods.

FDA authorizes initial Alzheimer's diagnosis through blood test

Title: Judy Benjamin, 80, embarks on 3,000-mile journey to showcase healthy aging amid Alzheimer's milestone

Paragraph 1: In a daring move to challenge the stigma around Alzheimer's, Judy Benjamin, 80, recently embarked on a 3,000-mile cross-country walk. This bold endeavor comes as the U.S. Food and Drug Administration (FDA) cleared the first-ever blood test to detect Alzheimer's disease, known as Lumipulse.

Paragraph 2: The Lumipulse, a game-changer in Alzheimer's diagnosis, works by identifying amyloid plaques, a telltale sign of the disease, in the brain. This blood test reduces the need for costly and time-consuming PET scans, which can expose patients to harmful radiation[1].

Paragraph 3: In a clinical study involving 499 plasma samples from cognitively impaired adults, the Lumipulse test accurately detected amyloid plaques in 91.7% of individuals[1]. This blood test can reliably predict the presence or absence of amyloid pathology associated with Alzheimer's disease in patients experiencing cognitive impairment[1].

Paragraph 4: However, false positive test results from Lumipulse could lead to unnecessary diagnosis and treatments, the FDA warned[1]. To address this, clinicians must use the test with caution and ensure they consider other factors, such as clinical evaluations, when making diagnoses.

Paragraph 5: FDA Commissioner Marty Makary, M.D., MPH, emphasized the impact of Alzheimer's, stating that it affects more people than breast cancer and prostate cancer combined[1]. With 10% of people aged 65 and older reported to have Alzheimer's, a number expected to double by 2050, he expressed hope for medical advancements like Lumipulse to help patients[1].

Paragraph 6: The approval of the Lumipulse blood test marks a significant stride in Alzheimer's diagnosis as it makes early detection more accessible for U.S. patients[1]. Industry experts have praised the innovation, believing it will revolutionize the way we approach and manage Alzheimer's[1].

Paragraph 7: Meanwhile, an 80-year-old Alzheimer's patient, Judy Benjamin, has chosen to take matters into her own hands. Despite her diagnosis 13 years ago, she has embarked on a cross-country journey to inspire others, demonstrating that life with Alzheimer's is not a death sentence but a testament to resilience and determination.

Additional Insights:- The Lumipulse blood test, developed by Fujirebio Diagnostics, measures the ratio between phosphorylated tau 217 (p-tau 217) and beta-amyloid 1-42[1][2][3].- The test is intended for individuals aged 55 and older who show signs of cognitive decline, helping to differentiate Alzheimer's from other forms of dementia when used alongside clinical information[2][4].- The potential impact of the Lumipulse blood test includes early diagnosis, convenience, better treatment options, and future research and development[2][3].

[1] Enrichment Data: "How the Lumipulse Blood Test Works"[2] Enrichment Data: "Potential Implications for Diagnosis and Treatment"[3] Enrichment Data: "Lumipulse Blood Test: A Breakthrough in Alzheimer's Diagnosis"[4] Enrichment Data: "Lumipulse Approval: Implications for the Diagnosis and Management of Alzheimer's"

  1. The Lumipulse blood test, a game-changer in Alzheimer's diagnosis, works by identifying amyloid plaques, a telltale sign of Alzheimer's, in the brain, and measures the ratio between phosphorylated tau 217 (p-tau 217) and beta-amyloid 1-42.
  2. Scientific advancements in technology, such as the Lumipulse blood test, could potentially lead to early diagnosis, convenience, better treatment options, and future research and development for neurological disorders like Alzheimer's disease.
  3. As mental health becomes an increasingly important aspect of health and wellness, especially among aging populations, technology plays a crucial role in addressing conditions like Alzheimer's disease and other neurological disorders, which affect more people than breast cancer and prostate cancer combined.
  4. Judy Benjamin, an 80-year-old Alzheimer's patient, embarks on a 3,000-mile journey to showcase healthy aging amid Alzheimer's milestone, demonstrating that a diagnosis of Alzheimer's does not equate to a sentence of inevitability, but rather a testament to resilience and determination.

Read also:

    Related

    Latest